Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Kidney Function Trajectories Before and After HF Hospitalisation
Author(s): Nicolas Girerd Added: 2 days ago
ESC HF 25 - Real-world findings suggest kidney function decline could precede heart failure events by up to a year.Prof Nicolas Girerd (University Hospital of Nancy, Nancy, FR) discusses real-world findings from pooled trials EPHESUS, EMPHASIS-HF and BARCELONA. The study investigated if longitudinal changes in kidney function could help identify patients with HFrEF at a higher risk of… View more

Cardiovascular Renal Metabolic

Heart Failure
ESCHFA25: FINEARTS-HF: Finerenone Risk-Benefit Across Kidney Function
Author(s): Safia Chatur Added: 3 days ago
ESC HF 25 - In a FINEARTS HF post-hoc analysis, the relative and absolute effects of finerenone relative to placebo did not significantly differ across kidney function.We are joined by Dr Safia Chatur (Mass General Cardiology, US) to discuss key findings from the FINEARTS-HF trial. This Phase 3 study evaluated the effect of finerenone versus placebo on cardiovascular death and total heart failure… View more

Cardiovascular Renal Metabolic

Heart Failure
HFSA 24: STEP-HFpEF: Exercise Function and Frailty Status
Author(s): Mikhail Kosiborod Added: 7 months ago
HFSA 24 - We are joined virtually by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss findings from the STEP-HFpEF trial programme in regard to the efficacy of semaglutide according to frailty status, and exercise function at baseline.Interview Questions:1. Could you remind us of the importance of STEP-HFpEF2. What was the study design and patient population?3. What… View more

Heart Failure

Prevention & Chronic Conditions
Effects of GLP-1 Receptor Agonists in Heart Failure Patients
Author(s): Anastasia Shchendrygina , Amina Rakisheva , Ilya Giverts , et al Added: 8 months ago

Heart Failure
EASD 24: Prespecified Analysis from the SELECT Trial
Author(s): Helen Colhoun Added: 7 months ago
EASD 24 - We are joined by Dr Helen Coulhoun (University of Edinburgh, UK) to discuss the key findings of a prespecified analysis of the SELECT trial, which investigated the effectiveness of semaglutide in reducing major cardiac events in the presence of impaired kidney function in patients with overweight and obesity.Findings showed that participants in the study with reduced eGFR and/or… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Portrait image of Stavros Stavrakis
Research Area(s) / Expertise:

Atrial Fibrillation

 Job title: Associate Professor of Medicine; Laureate Chair in Molecular Medicine; Vice Chief, Cardiovascular Section
Dr Stavrakis is a clinical cardiac electrophysiologist and Associate Professor of Medicine at the University of Oklahoma Health Sciences Center. He is also the Director of Cardiovascular Research at the University of Oklahoma. Dr Stavrakis’ research has focused on autonomic modulation for the treatment of arrhythmias and other cardiovascular diseases, in both animal models and humans. The… View more
Pierre Jaïs
Pierre Jaïs, MD a Professor at the Cardiology Hospital, Pessac, France, working with Michel Haïssaguerre in the Rhythmolgy & Cardiac Stimulation Department, co-manages the LIRYC Institute (Electrophysiology and Heart Modeling Institute) and the MUSIC EQUIPEX; both aim to improve knowledge and treatments of electrical dysfunctions of the heart with an extra focus on imaging for MUSIC. Dr Jaïs… View more